News & Media

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with hepatocellular carcinoma (HCC) has been dosed...

Press release 2021/12/01

Medivir to present at the Erik Penser Bank Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Erik Penser Bank Life...

Press release 2021/11/18

Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that results from the investigator-initiated phase II clinical study in patients...

Press release 2021/11/11

Medivir to present at the Redeye Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Life Science Day,...

Press release 2021/11/04

Birinapant clinical study initiated by IGM Biosciences

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid...

Press release 2021/11/03

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2021

Positive MIV-818 data presented at ESMO. New positive data and renegotiated agreement for remetinostat July – September Financial summary for the...

Press release 2021/10/28

Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the...

Press release 2021/10/25

Medivir Appoints Jens Lindberg as Chief Executive Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO...

Press release 2021/10/15

A joint patent application for MALT1 inhibitors published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a joint patent application for MALT1 inhibitors submitted together with...

Press release 2021/10/11

Medivir to present at the ProHearings shared Capital Markets Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets...

Press release 2021/09/16

Medivir invites to a conference call on new clinical data and further studies with MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed...

Press release 2021/09/13

Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled “Phase 1 study of the novel prodrug...